Publication
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (15)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 15
- cancerGliomacivic_curation1.00
- cancerLow Grade Gliomacivic_curation1.00
- drugVorasidenibcivic_curation1.00
- geneIDH1civic_curation1.00
- geneIDH2civic_curation1.00
- variantIDH1 Mutationcivic_curation1.00
- variantIDH1 R132Ccivic_curation1.00
- variantIDH1 R132Gcivic_curation1.00
- variantIDH1 R132Hcivic_curation1.00
- variantIDH1 R132Lcivic_curation1.00
- variantIDH1 R132Scivic_curation1.00
- variantIDH2 Mutationcivic_curation1.00
- variantIDH2 R172Gcivic_curation1.00
- variantIDH2 R172Kcivic_curation1.00
- variantIDH2 R172Wcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 37272516
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| IDH1 Mutation + IDH2 MutationIDH1IDH21 | ||||||||
| Vorasidenib | Glioma | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11708In this study, 331 patients with IDH-mutant grade 2 gliomas were either given vorasidenib (n = 168) or a placebo (n = 163). A median PFS of 27.7 months was reported in the vorasidenib group, compared … (full text at CIViC) PMID 37272516 · Mellinghoff et al., 2023 · Open in CIViC | civic |
| IDH1 R132C + IDH1 R132G + IDH1 R132H + IDH1 R132L + IDH1 R132S1 | ||||||||
| Vorasidenib | Low Grade Glioma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11508This phase 3 clinical trial was conducted to assess the progression free survival in patients with IDH-mutant gliomas treated with Vorasidenib, an oral brain-penetrant inhibitor, which showed prelimin… (full text at CIViC) PMID 37272516 · Mellinghoff et al., 2023 · Open in CIViC | civic |
| IDH2 R172G + IDH2 R172K + IDH2 R172W1 | ||||||||
| Vorasidenib | Low Grade Glioma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11509This phase 3 clinical trial was conducted to assess the progression-free survival in patients with IDH-mutant gliomas treated with Vorasidenib, an oral brain-penetrant inhibitor, which showed prelimin… (full text at CIViC) PMID 37272516 · Mellinghoff et al., 2023 · Open in CIViC | civic |
| IDH2 R172M + IDH2 R172S1 | ||||||||
| Vorasidenib | Low Grade Glioma | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12235This phase 3 clinical trial was conducted to assess the progression-free survival in patients with IDH-mutant gliomas treated with Vorasidenib, an oral brain-penetrant inhibitor, which showed prelimin… (full text at CIViC) PMID 37272516 · Mellinghoff et al., 2023 · Open in CIViC | civic |